PMID- 31172723
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2092-7355 (Print)
IS  - 2092-7363 (Electronic)
IS  - 2092-7355 (Linking)
VI  - 11
IP  - 4
DP  - 2019 Jul
TI  - Combination Effect of Titrated Extract of Centella asiatica and Astaxanthin in a 
      Mouse Model of Phthalic Anhydride-Induced Atopic Dermatitis.
PG  - 548-559
LID - 10.4168/aair.2019.11.4.548 [doi]
AB  - PURPOSE: In our previous study, we demonstrated that both titrated extract of 
      Centella asiatica (TECA) and astaxanthin (AST) have anti-inflammatory effects in 
      a 5% phthalic anhydride (PA) mouse model of atopic dermatitis (AD). The 
      increasing prevalence of AD demands new therapeutic approaches for treating the 
      disease. We investigated the therapeutic efficacy of the ointment form of TECA, 
      AST and a TECA + AST combination in a mouse model of AD to see whether a 
      combination of the reduced doses of 2 compounds could have a synergistic effect. 
      METHODS: An AD-like lesion was induced by the topical application of 5% PA to the 
      dorsal ear and back skin of an Hos:HR-1 mouse. After AD induction, TECA (0.5%), 
      AST (0.5%) and the TECA (0.25%) + AST (0.25%) combination ointment (20 mug/cm(2)) 
      were spread on the dorsum of the ear or back skin 3 times a week for 4 weeks. We 
      evaluated dermatitis severity, histopathological changes and changes in protein 
      expression by Western blotting for inducible nitric oxide synthase (iNOS), 
      cyclocxygenase (COX)-2, and nuclear factor (NF)-kappaB activity. We also measured the 
      concentrations of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and 
      immunoglobulin E (IgE) in the blood of AD mice by enzyme-linked immunosorbent 
      assay (ELISA). RESULTS: PA-induced skin morphological changes and ear thickness 
      were significantly reduced by TECA, AST and TECA + AST treatments, but these 
      inhibiting effects were more pronounced in the TECA + AST treatment. TECA, AST 
      and the TECA+AST reatments inhibited the expression of iNOS and COX-2; NF-kappaB 
      activity; and the release of TNF-alpha, IL-6 and IgE. However, the TECA+AST treatment 
      showed additive or synergistic effects on AD. CONCLUSIONS: Our results 
      demonstrate that the combination of TECA and AST could be a promising therapeutic 
      agent for AD by inhibiting NF-kappaB signaling.
CI  - Copyright (c) 2019 The Korean Academy of Asthma, Allergy and Clinical Immunology . 
      The Korean Academy of Pediatric Allergy and Respiratory Disease.
FAU - Park, Ju Ho
AU  - Park JH
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Korea.
FAU - Yeo, In Jun
AU  - Yeo IJ
AUID- ORCID: 0000-0002-6799-667X
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Korea.
FAU - Jang, Jun Sung
AU  - Jang JS
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Korea.
FAU - Kim, Ki Cheon
AU  - Kim KC
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Korea.
FAU - Park, Mi Hee
AU  - Park MH
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Korea.
FAU - Lee, Hee Pom
AU  - Lee HP
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Korea.
FAU - Han, Sang Bae
AU  - Han SB
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Korea.
FAU - Hong, Jin Tae
AU  - Hong JT
AUID- ORCID: 0000-0002-6534-9575
AD  - College of Pharmacy and Medical Research Center, Chungbuk National University, 
      Cheongju, Korea. jinthong@chungbuk.ac.kr.
LA  - eng
GR  - 2017R1A5A2015541/NRF/National Research Foundation of Korea/Korea
GR  - 1415139249/MOTIE/Ministry of Trade, Industry and Energy/Korea
PT  - Journal Article
PL  - Korea (South)
TA  - Allergy Asthma Immunol Res
JT  - Allergy, asthma & immunology research
JID - 101518382
PMC - PMC6557773
OTO - NOTNLM
OT  - Astaxanthin
OT  - NF-kappaB
OT  - atopic dermatitis
OT  - inflammation
OT  - titrated extract of Centella asiatica
COIS- There are no financial or other issues that might lead to conflict of interest.
EDAT- 2019/06/07 06:00
MHDA- 2019/06/07 06:01
PMCR- 2019/07/01
CRDT- 2019/06/08 06:00
PHST- 2018/05/10 00:00 [received]
PHST- 2019/01/02 00:00 [revised]
PHST- 2019/01/08 00:00 [accepted]
PHST- 2019/06/08 06:00 [entrez]
PHST- 2019/06/07 06:00 [pubmed]
PHST- 2019/06/07 06:01 [medline]
PHST- 2019/07/01 00:00 [pmc-release]
AID - 11.548 [pii]
AID - 10.4168/aair.2019.11.4.548 [doi]
PST - ppublish
SO  - Allergy Asthma Immunol Res. 2019 Jul;11(4):548-559. doi: 
      10.4168/aair.2019.11.4.548.